(Q37313436)

19 August 2017

1 reference

title

Cystatin C: current position and future prospects (English)

1 reference

19 August 2017

Sophie Séronie-Vivien

1

1 reference

19 August 2017

Pierre Delanaye

2

1 reference

19 August 2017

Laurence Piéroni

3

1 reference

19 August 2017

Christophe Mariat

4

1 reference

19 August 2017

Marc Froissart

5

1 reference

19 August 2017

Jean-Paul Cristol

6

1 reference

19 August 2017

SFBC "Biology of renal function and renal failure" working group

7

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Clinical Chemistry and Laboratory Medicine

19 August 2017

1 reference

19 August 2017

46

1 reference

19 August 2017

1664-1686

1 reference

19 August 2017

12

1 reference

The occurrence of post-gamma protein in urine: a new protein abnormality

19 August 2017

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Post- -globulin: isolation and physicochemical characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Human cystatin, a new protein inhibitor of cysteine proteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Determination of serum cystatin C: biological variation and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Reference intervals for serum cystatin C and serum creatinine in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Impact of age on reference values for serum concentration of cystatin C in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

GFR estimation using cystatin C is not independent of body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Is cystatin C useful for the detection and the estimation of low glomerular filtration rate in heart transplant patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Effect of malnutrition on serum creatinine and cystatin C levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Time course of low molecular weight proteins in the early kidney transplantation period--influence of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Beta-trace protein is not superior to cystatin C for the estimation of GFR in patients receiving corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Impact of thyroid dysfunction on serum cystatin C

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C is sensitive to small changes in thyroid function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Megalin-mediated endocytosis of cystatin C in proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Renal extraction of cystatin C vs 125I-iothalamate in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Urinary cystatin C as a specific marker of tubular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Measurement of cystatin-C and creatinine in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C--a new marker of glomerular filtration rate in children independent of age and height.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Is serum cystatin C the marker of choice to predict glomerular filtration rate in paediatric patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Comparison of cystatin C, creatinine and creatinine clearance vs. GFR for detection of renal failure in renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Interest of cystatin C in screening diabetic patients for early impairment of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C level as a potentially good marker for impaired kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Diagnostic efficiency of cystatin C and serum creatinine as markers of reduced glomerular filtration rate in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C assay for the detection of early renal impairment in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C as a marker of the renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

New predictive equations improve monitoring of kidney function in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Improved GFR estimation by combined creatinine and cystatin C measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Differences in glomerular filtration rate estimates by 2 cystatin C-based equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Glomerular filtration rate estimated by cystatin C among different clinical presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

GFR is better estimated by considering both serum cystatin C and creatinine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Derivation and validation of cystatin C-based prediction equations for GFR in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The combination of cystatin C and serum creatinine improves the monitoring of kidney function in patients with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

How to estimate GFR-serum creatinine, serum cystatin C or equations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The Cockcroft-Gault formula should not be used in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Comparison between creatinine and cystatin C-based GFR equations in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of cystatin C-based equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C-based equations: don't repeat the same errors with analytical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C blood level as a risk factor for death after heart surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The relationship between serum creatinine, serum cystatin C and glomerular filtration rate in pediatric renal transplant recipients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C as a marker of renal function immediately after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Prediction of glomerular filtration rate in renal transplant recipients: cystatin C or modification of diet in renal disease equation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Evaluation of renal function in transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Chronic kidney disease stage in renal transplantation classification using cystatin C and creatinine-based equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Chronic kidney disease in the elderly--how to assess risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C in the aged: relationships with health status

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Renal impairment associated with diabetes in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin-C and inflammatory markers in the ambulatory elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C improves the detection of mild renal dysfunction in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Prevalence of chronic kidney disease in Chinese HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Racial differences in end-stage renal disease rates in HIV infection versus diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C-immunoglobulin high-molecular-weight complexes in kidney and liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Alternative definition of acute kidney injury following liver transplantation: based on serum creatinine and cystatin C levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Model for end-stage liver disease (MELD) and allocation of donor livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and the risk of death and cardiovascular events among elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C deficiency in human atherosclerosis and aortic aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Genotype and Plasma Concentration of Cystatin C in Patients With Coronary Heart Disease and Risk for Secondary Cardiovascular Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin-C and mortality in elderly persons with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C: an emerging glomerular filtration rate marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Plasma cystatin-C and development of coronary heart disease: The PRIME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and subclinical brain infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C and mortality risk in the elderly: the health, aging, and body composition study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C, kidney function and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Kidney function as a predictor of noncardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C in patients with head and neck carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Pretreatment cystatin C in children with malignancy: can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Human Evidence That the Cystatin C Gene Is Implicated in Focal Progression of Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Factors associated with chronic renal failure in HIV-infected ambulatory patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

Outcome and Prognosis Factors in HIV-Infected Hemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2008.336

21 January 2018

Identifiers

DOI

10.1515/CCLM.2008.336

1 reference

release_24or2iurxjaenerjvpn6sgynka

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/24or2iurxjaenerjvpn6sgynka

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference